{"name":"Auron Therapeutics, Inc.","slug":"auron-therapeutics-inc","ticker":"","exchange":"","domain":"auron.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AUTX-703","genericName":"AUTX-703","slug":"autx-703","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AUTX-703","genericName":"AUTX-703","slug":"autx-703","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxORHBUV3B4U3FNS3BfS2kwblhEWU5XLWx3VndoMXFoaWVsNnJXVGxwVjdoSy1LTDZQQUdCaThQOEV3RXNMUHVWLWNzMnl0ZVI4cGF3eGFkdWdrNjhqNXUzbWx1cVdZTGNLQmNERm5NUlMyUzJvSGp0RFhWTndpQ3ZZYmQ2Qk9aeFpsSjd6aFZOdktvY285VFBQZ0V1eExVT0tSMXM1ek5pYU15ZmFBX21PRTF3cE9jU0lkazM4WXRxc0R6V19RUVlYclZxRGtoeUY0?oc=5","date":"2025-08-18","type":"regulatory","source":"Roswell Park Comprehensive Cancer Center","summary":"Phase 1 Clinical Trial Offers FDA Fast-Tracked Drug for Relapsed/Refractory AML and MDS - Roswell Park Comprehensive Cancer Center","headline":"Phase 1 Clinical Trial Offers FDA Fast-Tracked Drug for Relapsed/Refractory AML and MDS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQN2wzNFdHTDNla2x0M19VRTh3U3BPdzBjZGZIcU1XeWxlbnBMRzd4Q1N3U2dzcmNjS0tJMlFOa1N1YkxEWElaZWw4aFNLS2Y3MTY1LWdmUVdSaXdKdmc4cDY3WHNJSzFiSzNHbUx3SkpxUWtyVWYtMDQyUDJqSHVlYjcxb1VrcmVVc3FPXzRrZDc3Rmt0Wkp6cmFsSkwwMGl5U3UzS1k3d1hwZnBU?oc=5","date":"2025-06-27","type":"pipeline","source":"statnews.com","summary":"Proposed cuts could have ‘catastrophic effect,’ 110 biomedical, health sciences industry leaders tell Congress - statnews.com","headline":"Proposed cuts could have ‘catastrophic effect,’ 110 biomedical, health sciences industry leaders tell Congress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOWWZDWFR0RW1zRGJZMUpIZXZNcUx0QXFWVmgyS2JVSkctSG5reTNEREpmQjhid2JqanJtaF9EakwzcVFRTEp4cE1oSzQ2QmtoaTVPaTFOa0ZxSWM4aE4zVHU0VGRDdVcyaWQ4cDFCQlpuQno3b291WWVvbkJZT3JURw?oc=5","date":"2025-03-28","type":"regulatory","source":"Oncology News Central","summary":"Recent FDA Oncology Approvals: 5 Question Quiz - Oncology News Central","headline":"Recent FDA Oncology Approvals: 5 Question Quiz","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNNllSZ1k5SVVyazZ5RGNScklJOGczaXltUTRwcFhHVU9acjV5T1p0U0JoNFNoSnFSRzRaWkhpV0tBeWR1TWNhTFVQUTRfVVpyOXdxZFBOLVQtbk9lN0JJckFPMzRKNU81dTlaRjBGRkVQZ2lpSVY2OTltSHVMcGw5UnBldGJKRzJjc0xqYWRhOE9SaXQ0WmdmbU9xS1g?oc=5","date":"2025-03-03","type":"regulatory","source":"Oncology News Central","summary":"Oncology Drugs Fast-Tracked by the FDA in February 2025 - Oncology News Central","headline":"Oncology Drugs Fast-Tracked by the FDA in February 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNM2M5Rk1sck01SmpfekYwOXJHNGo1TnowbDhXVkNaUi1vdTJFVnc3eWc3Q0hrZkFvV211WnE0aWdSaUI0ZVpyYlNWU1dXV0pibklZZFNVaVczaDJNbWZJSUdmRXMwOEFQaEtVaWQ5NVhKbXc5cWtTR2NNMjdUdGpFUnF0bThFTFU3TUY4?oc=5","date":"2025-02-04","type":"pipeline","source":"The Business Journals","summary":"Newton biotech raises Series B to test cancer drug in the clinic - The Business Journals","headline":"Newton biotech raises Series B to test cancer drug in the clinic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZV9UTWZXNDNFUThld29hWTVER0dsRDhKZVRMbUUwTmJGS3k1VklhTmwwZ3JtTnpBY0NCczgxa1dvRHh1dWJVbDFhNEFYWDVwUl9ORHV0YjU2Y2RIeE9WOHYxRUpKUFZYU0djR3FSSW9QNXlLM2F3bmZjTm9WaDdIazFpUVFaQUMxVnY0LWRSeHBfNTZveTIyRW1UbDhCejB1T21MLTFKYkpZS2JJWW12STFWOGJ1dFRBM1Zj?oc=5","date":"2024-12-18","type":"pipeline","source":"BioWorld News","summary":"AUTX-703, a KAT2A/KAT2B degrader with efficacy in acute myeloid leukemia models - BioWorld News","headline":"AUTX-703, a KAT2A/KAT2B degrader with efficacy in acute myeloid leukemia models","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNUHgtdzBhTU5vUlJ2QXJndG93bEE4bElqbUZjWDVVSklIOHlsUVI1SDlFSXR1dE9JQ0p1Qjc4MjhnTXRRZXVxNTFEZUtQeTVZQ3RLdE9JTm00VFNVcWtIRU5CM3FUaFY0NWtWTmg1YWJ1MVY4Q2xLVXo1VGp5aU5peGprN2U1N2YwaW9zQ3pQSFg?oc=5","date":"2024-11-18","type":"pipeline","source":"Memorial Sloan Kettering Cancer Center","summary":"How Acute Myeloid Leukemia Is Treated at MSK: An Interview With Eytan Stein - Memorial Sloan Kettering Cancer Center","headline":"How Acute Myeloid Leukemia Is Treated at MSK: An Interview With Eytan Stein","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNQVJqMXVlWGNqQWM4aGtnR2lMMEZDMzE5amlONVhWOGN0QUJtMGt3MFpfbzZzdUxyOXhFemlCMTlBLTAwTjZ6aFlWN3BWNnhmZTI1MDB6VlprSmo5V3hibW55TUdnS001dXB0d2FqSnVvUk1sUlV1WXJyendYWEN3aFpVNXR3U0pOaWZSaGZUVUFBNmpXTlFGNUtnaTVGcFg0S2NuV3BR?oc=5","date":"2024-10-30","type":"pipeline","source":"BioWorld News","summary":"KAT2A/B degrader has activity in small-cell lung cancer models - BioWorld News","headline":"KAT2A/B degrader has activity in small-cell lung cancer models","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxOQUZCa00tbjVUbU82dzl2aFNidnJzWDlYaFlxcV9BNkRhS2xPcFB6bzh4R1JPbDRXbzZNT25QMHhjdVd4cVRNeHRKS1ZaNVdORFo3b0ZJSlY3QzE1YWpVMlRlWVFUV3g5eEplVHRoMVRtMzBwX0ctQ3M4R0ltM0hmNHYzdTRwWWtfdHg1Z2pzNWpFaXlPZU0zNHFYMUV6dHpVdVB2ck9ET0dDeFJsdnJLbkpONGRZbEpzQmJYdVpyTE1JSGVFaURFMEJOSG40VnUwZGZoYnZJRWZhdE9NMkFoN2NKcTdQckcwNFVaWWl5dFg5LUU5OHVJdEN0UjYxNjhlVFA1cmJLQTZpR0dYSk9FMG9WeGtlUk5VeFZsMkROaHhzLW5iZEMzTFI2cVZ6UkRhMFJR?oc=5","date":"2024-02-08","type":"pipeline","source":"GlobeNewswire","summary":"Auron Selects First Development Candidate for its Portfolio - GlobeNewswire","headline":"Auron Selects First Development Candidate for its Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBvWURlbUxfQWxIYV9iSVNQMDJqQ3A3cHhWbkMzaUdPUndmNWRKbl9EV2VDaGpkTlVuamt3dWNBMXZFdkZMNXpLXzhaYmxoOUhIMUN1M1RVbzBNZjludE1OcUJfT2VwVVF1QVE?oc=5","date":"2023-06-24","type":"regulatory","source":"Wiley Online Library","summary":"Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study - Wiley Online Library","headline":"Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1QZVByRnpqSm9kZFJHeHpiNUlDbk1SMnpZWnZ6eUtHand5eU90dHZTZ2ZNWnVXUEVmd1o3cm1KQ3hZaVJfVEs0MU1ydjJ1dERRYWk3SXJkbElqM3lwbzlHR1FVa3hBXzhMelhkV21pbmtTMHdNQkVPWXp3ck4?oc=5","date":"2022-12-21","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker: Enlaza launches with $61M; Enveda brings in $68M - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker: Enlaza launches with $61M; Enveda brings in $68M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPM0dOVGJmeWg5ejFMRGRiNkZ2S05sREtXY1hFcW5heThtdjRZTEp1dWMxYWFLS0R4ZExyTkhiRk50c3ZJUU9HSnpGMmowOV96Z0doLW5VZ3FfdUEzTjNkTUNfQk9aMmc5aVdidGk5UDdtcGhXWUVqOFB0RVhyNTVGQU5vWlEzRURUZlFHcVlwbFY5RGJMcVRVenQ3UFk4Q0RuM0k4?oc=5","date":"2022-10-26","type":"pipeline","source":"Timmerman Report","summary":"Biotech Executives Call for Action on Reproductive Health Rights - Timmerman Report","headline":"Biotech Executives Call for Action on Reproductive Health Rights","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}